Alkermes plc

NASDAQ:ALKS

Biotechnology

Healthcare
$46.85 +1.77%

+$0.79 today

Market cap
$7.87B
Beta
0.33
P/E (TTM)
49.1
EPS (TTM)
$0.92
52W Low $25.17High $45.76

Volume 1.39M

Average 2.33M

ALKS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Alkermes plcNASDAQ: ALKS

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 167.87M shares rose 1.7% year over year, in line with the +1.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Weighted avg shares increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1.7% holds above the trailing-twelve-month pace of +1.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
167.87M+0.8% QoQ
Last fiscal yearDec 2025
164.7M-0.4% YoY
LTMSep 2026
166.35M+1.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.7%——
1 year-0.4%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
164.7M USD
Year-over-year change
-0.4%
4-year CAGR
+0.6%

Weighted Avg Shares vs competitors

How ALKS compares with its peers on the latest reported figures

  • ALKS's LTM Sep 2026 weighted avg shares of 166.35M shares is the 2nd highest of the 7 companies compared; the peer median is 60.9M shares.
  • Its year-over-year change of +1.5% is the 5th highest of 7, against a peer median of +2.6%.
  • Over three fiscal years its annual growth of +0.2% compares with a peer median of +1.5%.
ALKS Competitors Peer median
Weighted Avg Shares for ALKS and competitors
Company Period LTM YoY 3-year CAGR
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026171M +2.1%+1.6%
ALKSAlkermes plcLTM Sep 2026166.35M +1.5%+0.2%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026100.65M +1.1%+1.3%
JAZZJazz Pharmaceuticals plcLTM Sep 202662.7M +3.0%-0.8%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.4%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202657.36M +3.1%+1.7%
AXSMAxsome Therapeutics, Inc.LTM Jun 202650.84M +4.3%+7.0%
Peer median (excluding ALKS) 60.9M+2.6%+1.5%

Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.17B1.11B1.66B1.56B1.48B
Cost of Revenue197.32M218.07M253.04M245.33M196.46M
Gross Profit976.43M893.73M1.41B1.31B1.28B
Gross Margin83.2%80.4%84.8%84.2%86.7%
Research & Development290.92M272.7M270.81M245.33M323.96M
Selling, General & Admin549.61M590.75M689.75M645.24M714.52M
Operating Expenses878.68M899.82M996.25M891.67M1.03B
Depreciation & Amortization78.65M77.86M74.93M28.53M27.17M
EBITDA177.6M59.77M519.48M494.86M330.89M
EBITDA Margin15.1%5.4%31.2%31.8%22.4%
Operating Income97.75M(6.09M)414.12M420.64M253.96M
Operating Margin8.3%-0.5%24.9%27.0%17.2%
Interest Income2.41M7.63M30.85M42.45M45.3M
Interest Expense11.22M13.04M23.03M22.58M12.28M
Other Income / Expenses(10.02M)(25.04M)7.4M23.11M37.49M
Income Before Tax87.73M(31.13M)421.52M443.75M291.45M
Pre-Tax Margin7.5%-2.8%25.3%28.5%19.7%
Income Tax Expense11.33M2.02M(97.64M)71.61M49.79M
Net Income(48.17M)(158.27M)355.76M367.07M241.66M
Net Margin-4.1%-14.2%21.4%23.6%16.4%
EPS (Basic)(0.30)(0.97)2.142.221.47
EPS (Diluted)(0.30)(0.97)2.102.171.43
Weighted Avg Shares160.94M163.74M166.22M165.39M164.7M
Weighted Avg Shares (Diluted)160.94M163.74M169.73M169.2M168.74M

Alkermes plc

NASDAQ:ALKS

Intrinsic Alpha fair value

Locked

Current Price

$46.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.